PFE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
15.0B
+4.0%
14.4B
-17.7%
17.6B
+5.4%
16.7B
+13.7%
14.7B
Cost of Revenue
4.1B
+15.3%
3.5B
-32.7%
5.3B
+26.4%
4.2B
+10.4%
3.8B
Gross Profit
10.9B
+0.4%
10.9B
-11.3%
12.3B
-1.6%
12.5B
+14.8%
10.9B
Operating Expenses
7.9B
+14.7%
6.9B
-27.0%
9.4B
+9.1%
8.6B
+21.7%
7.1B
R&D
2.8B
+12.8%
2.5B
-22.3%
3.2B
+25.9%
2.5B
+2.6%
2.5B
SG&A
3.4B
+15.2%
3.0B
-28.9%
4.2B
+30.6%
3.2B
-6.7%
3.4B
Operating Income
3.1B
-24.0%
4.0B
+40.5%
2.9B
-25.5%
3.9B
+1.8%
3.8B
EBITDA
5.2B
-12.3%
5.9B
+9.4%
5.4B
-25.2%
7.2B
+33.3%
5.4B
Net Income
-238000000
-108.8%
2.7B
+264.4%
-1640000000
-146.2%
3.5B
+21.2%
2.9B
EPS (Basic)
$-0.04
-108.5%
$0.47
+262.1%
$-0.29
-146.8%
$0.62
+21.6%
$0.51
EPS (Diluted)
$-0.04
-108.5%
$0.47
+262.1%
$-0.29
-146.8%
$0.62
+21.6%
$0.51
Shares (Diluted)
5.7B
-0.6%
5.7B
+0.2%
5.7B
+0.1%
5.7B
+0.1%
5.7B
Pfizer (PFE) โ€” Financials